Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19227561 | BRAIN ORGANOID CONTAINING OPTIC VESICLES GENERATED BASED ON H9 INDUCTION AND EYE-BRAIN FUSION CULTURE METHOD | June 2025 | February 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 18650881 | ENGINEERED IMMUNE CELLS WITH RECEPTOR SIGNAL STRENGTH MODULATED BY A HINGE | April 2024 | July 2025 | Allow | 14 | 1 | 0 | No | No |
| 18503557 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY | November 2023 | July 2025 | Abandon | 20 | 2 | 1 | No | No |
| 18328473 | SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINS | June 2023 | September 2024 | Allow | 16 | 2 | 1 | No | No |
| 17957998 | OPTICALLY CONTROLLABLE FGFR STIMULATION USING WIRELESS CONTROLLED CELLULAR LIGHTING SYSTEM | September 2022 | November 2025 | Abandon | 38 | 4 | 0 | Yes | No |
| 17946894 | SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINS | September 2022 | February 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17878628 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17874433 | METHOD FOR EFFICIENTLY INDUCING REPROGRAMMING OF HUMAN CELL INTO NEURONAL CELL | July 2022 | June 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17663372 | MICROENCAPSULATION-BASED ISOLATION OF HUMAN PLURIPOTENT AND MULTIPOTENT STEM CELLS AND METHODS OF MAKING AND USING THE SAME | May 2022 | March 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17728956 | Differentiation of Olfactory Mucosa Derived Mesenchymal Stem Cells to Schwann Cells for Peripheral Nerve Repair | April 2022 | October 2024 | Allow | 30 | 3 | 1 | No | No |
| 17723159 | ENGINEERED CATFISH AND USES THEREOF | April 2022 | August 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17681647 | RETROVIRAL VECTORS | February 2022 | July 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17582730 | CHEMICALLY DEFINED MEDIUM FOR DIFFERENTIATION OF MUSCLE STEM CELLS IN VITRO | January 2022 | September 2025 | Abandon | 43 | 4 | 1 | Yes | No |
| 17578955 | ENGINEERED ANTIGEN PRESENTING CELLS | January 2022 | July 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17552464 | Animal Model for SARS-CoV-2-Spike Induced Coagulopathy | December 2021 | February 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17545034 | MESENCHYMAL STEM CELL CULTURE PRODUCT AND METHOD FOR PREPARING THE SAME | December 2021 | February 2025 | Abandon | 38 | 3 | 1 | Yes | No |
| 17512496 | PROTECTION AND REGENERATION OF NEUROLOGICAL FUNCTION BY USING STEM CELLS | October 2021 | August 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17497364 | VASCULARIZED ORGANOID MODEL INCORPORATING ISOLATED HUMAN MICROVESSEL FRAGMENTS | October 2021 | March 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17600432 | Improved Manufacturing Procedures for Cell Based Therapies | September 2021 | February 2026 | Abandon | 53 | 3 | 0 | No | No |
| 17487926 | ASCL1 VECTOR | September 2021 | November 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17480490 | ENGINEERED IMMUNE CELLS WITH RECEPTOR SIGNAL STRENGTH MODULATED BY A HINGE | September 2021 | January 2024 | Allow | 28 | 2 | 0 | No | No |
| 17458909 | ENGINEERED ONCOLYTIC VIRUSES EXPRESSING PD-L1 INHIBITORS AND USES THEREOF | August 2021 | November 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17397073 | LUNG BREATHING CHIP AND CELL STRETCHING CULTURE PLATFORM AND OPERATING METHOD THEREOF | August 2021 | September 2025 | Abandon | 50 | 5 | 1 | No | No |
| 17426389 | RECOMBINANT NUCLEIC ACIDS CONTAINING ALPHAHERPESVIRUS PROMOTER SEQUENCES | July 2021 | October 2025 | Allow | 50 | 2 | 1 | No | No |
| 17443415 | KITS AND METHOD OF MODIFYING, DETECTING, AND SORTING ANTIBODY-PRODUCING CELLS | July 2021 | September 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17347360 | TRANSIENT REPORTERS AND METHODS FOR BASE EDITING ENRICHMENT | June 2021 | April 2025 | Allow | 46 | 4 | 1 | No | No |
| 17324169 | CELL-CONTAINING VESSEL AND METHOD FOR PRODUCING NEURAL CELL-CONTAINING SPHEROID | May 2021 | November 2024 | Abandon | 42 | 4 | 1 | Yes | No |
| 17237498 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS | April 2021 | October 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17283942 | METHOD FOR FABRICATION OF THREE-DIMENSIONAL LUNG ORGANOID COMPRISING HUMAN STEM CELL-DERIVED ALVEOLAR MACROPHAGE | April 2021 | September 2024 | Allow | 41 | 2 | 1 | No | No |
| 17213299 | METHOD OF USING A TLR9 ANTAGONIST AS AN ANTI-INFLAMMATORY AND ANTI-FIBROTIC AGENT | March 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17277637 | METHODS OF PRODUCING VENOUS ANGIOBLASTS AND SINUSOIDAL ENDOTHELIAL CELL-LIKE CELLS AND COMPOSITIONS THEREOF | March 2021 | January 2026 | Abandon | 58 | 2 | 1 | No | No |
| 17277241 | PHARMACEUTICAL PRODUCT FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE | March 2021 | August 2025 | Abandon | 53 | 2 | 0 | No | No |
| 17194972 | PRODUCTION OF EXTRACELLULAR VESICLES FROM STEM CELLS | March 2021 | August 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 17182422 | ANTI-CD33 AND NKG2D LIGAND CHIMERAS FOR TREATMENT OF MYELOID MALIGNANCIES | February 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17172818 | MODIFICATION OF HEAVY CHAIN FIBROIN IN BOMBYX MORI | February 2021 | February 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17152220 | OPTICALLY CONTROLLABLE FGFR STIMULATION USING WIRELESS CONTROLLED CELLULAR LIGHTING SYSTEM | January 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17129527 | PRESERVATION OF PHAGE CONCENTRATION IN CLINICAL SAMPLES | December 2020 | December 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17254263 | GENERATION OF A POPULATION OF HINDBRAIN CELLS AND HINDBRAIN-LIKE ORGANOIDS FROM PLURIPOTENT STEM CELLS | December 2020 | October 2025 | Allow | 58 | 2 | 1 | No | No |
| 17247661 | EXTRACELLULAR VESICLES DERIVED FROM OSTEOBLAST LINEAGE CELLS FOR THERAPEUTIC AND DIAGNOSTIC USE | December 2020 | February 2025 | Abandon | 50 | 3 | 1 | Yes | No |
| 17118555 | COMPOSITION AND METHOD FOR INDUCTION OF PLURIPOTENT STEM CELL | December 2020 | December 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17116332 | GENOME-EDITED INDUCED PLURIPOTENT STEM CELLS, AND CELLS DERIVED THEREFROM, AND USES THEREOF | December 2020 | August 2024 | Allow | 44 | 1 | 1 | No | No |
| 16973108 | ENGINEERED HEMATOPOIETIC STEM CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | December 2020 | November 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17104528 | PLATELETS LOADED WITH mRNA | November 2020 | June 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17058245 | METHOD FOR THE VITRIFICATION OF HUMAN SEMEN AND PORTABLE KIT FOR THE APPLICATION OF SAID METHOD | November 2020 | October 2025 | Allow | 59 | 4 | 1 | No | No |
| 17058163 | COMBINATION THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17055673 | GENE THERAPY VECTORS COMPRISING S/MAR SEQUENCES | November 2020 | October 2025 | Abandon | 59 | 3 | 1 | No | No |
| 17053668 | CELL SCAFFOLD MATERIAL | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17050312 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS | October 2020 | September 2025 | Abandon | 59 | 3 | 1 | Yes | No |
| 17049974 | NUCLEIC ACID MOLECULES AND DUAL-FUNCTIONAL PEPTIDES HAVING ANTIVIRAL ACTIVITY AND DELIVERY ACTIVITY, COMPOSITIONS AND METHODS THEREOF | October 2020 | February 2026 | Allow | 60 | 3 | 1 | Yes | No |
| 17043836 | Composition For Inducing Dedifferentiation From Somatic Cells To Induced Pluripotent Stem Cells And Method of Inducing Dedifferentiation Using Same | September 2020 | March 2024 | Allow | 42 | 1 | 1 | No | No |
| 17036476 | COMPOSITION THAT CONTAINS POLYLYSINE ANALOG AND PROMOTES CELL GROWTH | September 2020 | February 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17040623 | METHODS OF CYTOPLASMIC INCOMPATIBILITY-BASED TRANSGENICS FOR PEST OR VECTOR CONTROL | September 2020 | March 2026 | Abandon | 60 | 4 | 1 | No | No |
| 16981421 | CRYOPRESERVING PROCESSES | September 2020 | January 2024 | Allow | 40 | 1 | 0 | No | No |
| 16981077 | REAGENTS AND METHODS WITH WNT AGONISTS AND BIOACTIVE LIPIDS FOR GENERATING AND EXPANDING CARDIOMYOCYTES | September 2020 | June 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 16979956 | STEPWISE METHOD OF PRODUCING VARIOUS TYPES OF CELLS FROM PLURIPOTENT STEM CELLS | September 2020 | August 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 16979215 | DENTAL ADHESIVE HYDROGELS AND USES THEREOF | September 2020 | September 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16978573 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | September 2020 | April 2025 | Allow | 55 | 2 | 1 | No | No |
| 16977106 | COMPOSITIONS FOR USE IN THE TREATMENT OF MUSCULOSKELETAL CONDITIONS AND METHODS FOR PRODUCING THE SAME LEVERAGING THE SYNERGISTIC ACTIVITY OF TWO DIFFERENT TYPES OF MESENCHYMAL STROMAL/STEM CELLS | September 2020 | November 2024 | Abandon | 50 | 3 | 1 | Yes | No |
| 16976581 | Compositions and Methods for Efficient Amplification of Retinal Progenitors Cells | August 2020 | August 2025 | Allow | 59 | 4 | 1 | Yes | No |
| 16971634 | MORPHOGENIC COMPOUND-RELEASING MICROSPHERES AND USE IN BIOINK | August 2020 | May 2025 | Abandon | 57 | 3 | 1 | Yes | No |
| 16994336 | METHODS FOR NUCLEAR REPROGRAMMING OF CELLS | August 2020 | March 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16958013 | ARTIFICIAL TISSUE PERFUSION DEVICE AND METHOD OF DRUG ASSESSMENT USING ARTIFICIAL TISSUE | July 2020 | April 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16962880 | METHOD FOR PRODUCING EXOSOMES AND EXOSOMES OBTAINED THEREBY | July 2020 | June 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16957010 | MESENCHYMAL STROMAL CELLS AND METHODS FOR OBTAINING MESENCHYMAL STROMAL CELLS FROM UMBILICAL CORD | June 2020 | November 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16956500 | METHOD FOR ISOLATING HUMAN DERMAL FIBROBLASTS | June 2020 | March 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16652803 | APPLICATION OF PLURIPOTENT STEM CELLS HAVING MODIFIED DIFFERENTIAL POTENTIAL TO PRODUCING ANIMALS | June 2020 | September 2023 | Abandon | 42 | 1 | 1 | Yes | No |
| 16756067 | CARTILAGE TISSUE PRODUCING METHOD AND CARTILAGE TISSUE | April 2020 | January 2024 | Abandon | 45 | 2 | 0 | No | No |
| 16820316 | METHOD FOR THE TREATMENT OF CANCERS BY MEANS OF GENETIC NEUROENGINEERING | March 2020 | October 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16644808 | NOVEL CELL LINE AND USES THEREOF | March 2020 | July 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16641137 | BIOENGINEERED IN VITRO 3D MODEL OF HUMAN ATHEROSCLEROTIC PLAQUE | February 2020 | November 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16638693 | COMPOSITIONS AND METHODS FOR ENHANCING MATURATION STATES OF HEALTHY AND DISEASED CARDIOMYOCYTES | February 2020 | May 2024 | Abandon | 51 | 2 | 1 | No | No |
| 16638483 | METHODS OF MATURATION OF HUMAN SPERMATOGONIUM | February 2020 | July 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16776503 | COMPOSITIONS AND METHODS FOR REGULATING PROTEINS AND NUCLEIC ACIDS ACTIVITIES | January 2020 | December 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16629402 | THE METHOD OF AUTOLOGOUS PRIMARY HAIR FOLLICLES PREPARATION IN 3D CULTURE | January 2020 | October 2024 | Allow | 58 | 5 | 0 | No | No |
| 16607836 | GENERATING HUMAN CELLS CAPABLE OF PRODUCING INSULIN IN RESPONSE TO GLUCOSE OR GLP-1 | October 2019 | July 2024 | Abandon | 57 | 1 | 1 | No | No |
| 16331410 | COMPOSITIONS AND METHODS FOR EVALUATING AND MODULATING IMMUNE RESPONSES | March 2019 | October 2025 | Abandon | 60 | 4 | 2 | Yes | No |
| 15536725 | TRANSGENIC RPE CELLS OVEREXPRESSING OTX2 FOR THE TREATMENT OF RETINAL DEGENERATION | June 2017 | August 2023 | Allow | 60 | 7 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner STAVROU, CONSTANTINA E works in Art Unit 1632 and has examined 63 patent applications in our dataset. With an allowance rate of 39.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner STAVROU, CONSTANTINA E's allowance rate of 39.7% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STAVROU, CONSTANTINA E receive 2.21 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by STAVROU, CONSTANTINA E is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.8% benefit to allowance rate for applications examined by STAVROU, CONSTANTINA E. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 31.8% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.